Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients
Phase 2
Completed
- Conditions
- Hormone-Refractory Prostate Cancer
- Interventions
- Drug: Zoledronic Acid 20mg Tablets
- First Posted Date
- 2008-03-14
- Last Posted Date
- 2009-02-20
- Lead Sponsor
- Merrion Pharmaceuticals, LLC
- Target Recruit Count
- 30
- Registration Number
- NCT00636740
- Locations
- 🇺🇸
Birmingham Hematology & Oncology Associates, LLC, Birmingham, Alabama, United States
🇺🇸Cancer Care of North Florida, P.A., Lake City, Florida, United States
🇺🇸Lakeland Regional Cancer Center, Lakeland, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath